Dr Christophe Berthoux CEO of Synexus has spearheaded a complete overhaul of the company’s management structure over the last two years. He says the firm’s top team now better reflects its extensive global presence and its culture of professionalism and continuous improvement.
The Synexus global executive team now comprises; Berthoux; Jane Restorick, Chief Operating Officer; Chris Hannigan, Commercial Director; Paul Chambers, Chief Financial Officer; Glynis Neagle, Chief Medical Officer and Wendy Ingham, Group Human Resources Director.
Supporting them is the global management team of Alison Martin, VP International Projects; Tony Healy, Group IT Director and Janet Jones, who recently joined the firm from CRO Icon, VP Access to Patients.
Our management team is composed of some of the most experienced people in the industry
A new regional structure – reporting to Restorick – is headed by regional directors who are responsible for the day to day running of the dedicated research centres in their territories, new business and profitability.
Klaus-Dieter Albrecht, who has been appointed as Managing Director of Synexus Germany, is responsible for the management of the seven Synexus dedicated clinical trial centres in Germany. Sanet Aspinall, Managing Director of Synexus South Africa, is responsible for the two centres in South Africa. Radoslaw Janiak is Managing Director of Synexus Central and Eastern Europe with responsibility for eight centres in Poland, Bulgaria, Ukraine, and Hungary. Angela Harnick is Operational Director of the UK responsible for seven centres across England, Wales and Scotland.
Berthoux said: ‘Our management team is composed of some of the most experienced people in the industry. They are delivering to our clients in pharma and CROs the numbers of patients they need and excellent quality data from all of our 25 dedicated research centres across the world.
‘Rather than being a totally centralised organisation, we have a management structure that provides comprehensive support but also recognises and enables the regional teams to run their own operations. In particular with regards patient acquisition it is vital that these activities are in line with the health systems in each country. This blend of local initiatives operating within a very tight regulatory framework allows the company to move forward much more rapidly.’